Evidence map›Paper›PMID 39289313›Full record

ArticleTargeted oncology2024

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Daniele Santini, Haoran Li, Giandomenico Roviello, Se Hoon Park, Enrique Grande, Jakub Kucharz, Umberto Basso, Ondrej Fiala, Fernando Sabino Marques Monteiro, Alexandr Poprach and 24 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Targeted oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Daniele SantiniDepartment of Radiological, Oncological and Pathological Sciences, Policlinico Umberto I, University of Rome, Rome, Italy.
Haoran LiDepartment of Internal Medicine, Division of Medical Oncology, University of Kansas Cancer Center, Westwood, KS, USA.
Giandomenico RovielloDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Se Hoon ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Enrique GrandeDepartment of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
Jakub KucharzDepartment of Uro-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Warsaw, Poland.
Umberto BassoMedical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
Ondrej FialaDepartment of Oncology and Radiotherapeutics, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
Fernando Sabino Marques MonteiroLatin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.
Alexandr PoprachMasaryk Memorial Cancer Institute, Brno, Czech Republic.
Sebastiano ButiDepartment of Medicine and Surgery, University of Parma - Oncology Unit, University Hospital of Parma, Parma, Italy.
Javier Molina-CerrilloDepartment of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain.
Martina CatalanoDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
Tomas BuchlerDepartment of Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Emmanuel SerontDepartment of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Jawaher AnsariMedical Oncology, Tawam Hospital, Al Ain, United Arab Emirates.
Zin W MyintMarkey Cancer Center, University of Kentucky, Lexington, KY, USA.
Marwan GhosnHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Fabio CalabròMedical Oncology, IRCCS, National Cancer Institute Regina Elena, Rome, Italy.
Ray Manneh KoppClinical Oncology, Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia.
Dipen BhuvaDepartment of Medical Oncology, Army Hospital Research and Referral, New Delhi, India.
Maria T BourlonInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Michela RobertoDepartment of Hematology, Oncology and Dermatology, UOC Oncologia A, Policlinico Umberto I University Hospital, Sapienza University of Rome, Rome, Italy.
Mattia Alberto Di CivitaDepartment of Hematology, Oncology and Dermatology, UOC Oncologia A, Policlinico Umberto I University Hospital, Sapienza University of Rome, Rome, Italy.
Veronica MollicaMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrea MarchettiMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrey SoaresLatin American Cooperative Oncology Group - LACOG, Porto Alegre, Brazil.
Nicola BattelliOncology Unit, Macerata Hospital, Macerata, Italy.
Marco RicciGeneral Director AST3, Macerata, Italy.
Ravindran KanesvaranNational Cancer Centre Singapore, Singapore, Singapore.
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, School of Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Camillo PortaInterdisciplinary Department of Medicine, Division of Medical Oncology, University of Bari "Aldo Moro", AOU Consorziale Policlinico di Bari, Bari, Italy.
Francesco Massari *Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.ORCID 0000-0001-6476-6871
Matteo Santoni *Oncology Unit, Macerata Hospital, Macerata, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTherapeutic advancements based on immuno-oncology combinations have revolutionized the management of patients with renal cell carcinoma. However, patients who have progressive disease as the best response, "primary refractory" (P

objectiveOur multicenter retrospective real-world study aims to assess the prevalence and clinicopathological characteristics of P

methodsThis study collected data from 72 centers across 22 countries (1709 patients), involving patients aged ≥18 years with metastatic clear cell renal cell carcinoma. All patients were treated with first-line immune-oncology combinations. Data included patient demographics, histology, metastatic sites, and treatment responses. Radiological assessments followed Response Evaluation Criteria in Solid Tumors version 1.1. Statistical analyses employed Kaplan-Meier method, Cox proportional hazard models, logistic regression, and the receiver operating characteristic curve.

resultsIn our study, the P

conclusionsThe ARON-1 study provides valuable insights into P

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID39289313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.